Undisclosed Aptamer Program
Wet Age-Related Macular Degeneration (wAMD)
Key Facts
About Drive Therapeutics
Drive Therapeutics is a private, preclinical-stage biotech company developing next-generation aptamer therapeutics for major retinal diseases like wAMD and DME. The company leverages a proprietary aptamer platform designed to generate long-acting, highly specific ocular therapies that could offer improved efficacy and reduced dosing frequency compared to current anti-VEGF standards. With a founding team of industry veterans and backing from non-dilutive grants like an NSF SBIR Phase 1 award, Drive is positioned to advance its pipeline candidates. The company operates in a large market with significant unmet need, as a substantial portion of patients do not respond adequately to existing treatments.
View full company profileAbout Drive Therapeutics
Drive Therapeutics is a private, preclinical-stage biotech company developing next-generation aptamer therapeutics for major retinal diseases like wAMD and DME. The company leverages a proprietary aptamer platform designed to generate long-acting, highly specific ocular therapies that could offer improved efficacy and reduced dosing frequency compared to current anti-VEGF standards. With a founding team of industry veterans and backing from non-dilutive grants like an NSF SBIR Phase 1 award, Drive is positioned to advance its pipeline candidates. The company operates in a large market with significant unmet need, as a substantial portion of patients do not respond adequately to existing treatments.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (wAMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| UBX1325 (foselutoclax) | Unity Biotechnology | Phase 2 |
| RGX-314 | ReGenX Biosciences | Phase II |